Processa Pharmaceuticals Inc Stock
Processa Pharmaceuticals Inc Stock price
Key metrics
| Market capitalization | $1.16m |
| Enterprise Value | $40.00k |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 0.48 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-12.05m |
| Free Cash Flow (TTM) Free Cash Flow | $-11.25m |
| Cash position | $1.19m |
Is Processa Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.
Processa Pharmaceuticals Inc Stock Analysis
Analyst Opinions
2 Analysts have issued a Processa Pharmaceuticals Inc forecast:
Analyst Opinions
2 Analysts have issued a Processa Pharmaceuticals Inc forecast:
Financial data from Processa Pharmaceuticals Inc
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -12 -12 |
6%
6%
|
EBIT (Operating Income) EBIT | -12 -12 |
5%
5%
|
| Net Profit | -12 -12 |
7%
7%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Processa Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Processa Pharmaceuticals Inc Stock News
Company Profile
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.
| Head office | United States |
| CEO | George Ng |
| Employees | 10 |
| Founded | 2011 |
| Website | www.processapharmaceuticals.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
